Key result
Elevated PARK7 and NDKA identify acute stroke within 3 hours with up to ~97% specificity.
Case-Control (n=787)
Yes
BACKGROUND: Plasma markers for stroke could be useful in diagnosis and prognosis and in prediction of response of stroke patients to therapy. PARK7 and nucleoside diphosphate kinase A (NDKA) are increased in human postmortem cerebrospinal fluid (CSF), a model of global brain insult, suggesting that measurement in CSF and, more importantly, in plasma may be useful as a biomarker of stroke. METHODS: We used ELISA to measure PARK7 and NDKA in plasma in 3 independent European and North American retrospective studies encompassing a total of 622 stroke patients and 165 control individuals. RESULTS: Increases in both biomarkers were highly significant, with sensitivities of 54%-91% for PARK7 and 70%-90% for NDKA and specificities of 80%-97% for PARK7 and 90%-97% for NDKA. The concentrations of both biomarkers increased within 3 h of stroke onset. CONCLUSIONS: PARK7 and NDKA may be useful plasma biomarkers for the early diagnosis of stroke. In addition, this study demonstrated the utility of analysis of postmortem CSF proteins as a first step in the discovery of plasma markers of ischemic brain injury.
No takes yet. Share an insight, caveat, or question.
Allard et al. (2005) conducted a case-control in Stroke (n=787). PARK7 and Nucleoside Diphosphate Kinase A (NDKA) plasma biomarkers vs. Healthy controls was evaluated on Sensitivities and specificities of PARK7 and NDKA for early diagnosis of stroke. Plasma levels of PARK7 and NDKA increased within 3 hours of stroke onset, yielding diagnostic sensitivities of 54-91% and 70-90% and specificities of 80-97% and 90-97%, respectively.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More from Clinical Chemistry